
Gene Therapy Breakthrough Brings Hope to Black Americans Living With Sickle Cell
A Louisiana man became the state’s first functionally cured sickle cell patient via 2023 FDA-approved gene therapies Casgevy and Lyfgenia; while these treatments hold promise for tens of thousands who are Black or African American, their high cost (around $2–$3 million) and limited treatment centers create access barriers, highlighting the need for broader insurance coverage, expanded care in underserved communities, and thorough discussion of risks like infertility and long‑term cancer risk.

